Winter Quarter Our paper, “Multipath Natural Product Suplement Supresses Dementia Symptoms in Amyloid-B and Tau Transgenic Drosophila” is published in The Journal of Biology and Medical Research in January. Work continues on a paper detailing our human pilot study results, “Botanical Mixture Stabilizes Cognitive Function in Patients with Mild and Moderate Alzheimer’s Disease.” Spring Quarter […]
August 17, 2018 Abstract Context: Currently, there is no treatment that can stop the progression of Alzheimer’s disease. We have used transgenic Drosophila melanogaster models and machine learning to develop an eight component botanical mixture (Geneaire™ ReBuilder™) that targets multiple genetic pathways involved in brain aging and dementia that are homologous between Drosophila and humans. […]
January 18, 2018 Abstract Background: Numerous reports on Alzheimer’s Disease (AD) indicate that AD has many biochemical pathways. However, most AD treatments have targeted a single pathway such as beta amyloid or phosphorylated tau and have not been very successful in stopping AD progression. To address the multipath nature of AD, we have used multiple […]
Genescient Corporation and Kronos Science Laboratory will work together to analyze the Kronos Alzheimer’s Case-Control Database, considered to be the finest Alzheimer’s Disease genetic data set in the US. The companies hope to identify genes previously unrecognized genes that are involved in Alzheimer’s Disease.